Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17634041 | 0.86 | SMN1; SMN2 (0.45) | SMN1; SMN2 | |
| SCHEMBL17634052 | 0.86 | SMN1; SMN2 (0.45) | SMN1; SMN2 | |
| SCHEMBL17638810 | 0.86 | SMN1; SMN2 (0.45) | SMN1; SMN2 | |
| SCHEMBL19300209 | 0.77 | SMN1; SMN2 (0.37) | SMN1; SMN2 | |
| SCHEMBL19300027 | 0.77 | SMN1; SMN2 (0.37) | SMN1; SMN2 | |
| SCHEMBL20408741 | 0.74 | SMN1; SMN2 (0.35) | SMN1; SMN2 | |
| SCHEMBL6830271 | 0.70 | — | — | |
| SCHEMBL24250131 | 0.68 | SMN1; SMN2 (0.36) | SMN1; SMN2 | |
| SCHEMBL17634066 | 0.68 | TP53 (0.33) | — | |
| SCHEMBL17634047 | 0.68 | TP53 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10457648-B2 | Process for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds | GENENTECH INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20170247338-A1 | PROCESS FOR PREPARING (CYCLOPENTYL[d]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS | F. HOFFMAN-LA ROCHE AG (CH) | 2017-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247338-A1 | PROCESS FOR PREPARING (CYCLOPENTYL[d]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS | PAK5, CDK5, PPIP5K2 | SMN1; SMN2 2538/4885 |
| US-10457648-B2 | Process for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds | PAK5, CDK5, PPIP5K2 | SMN1; SMN2 2538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.